JP2018523978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523978A5 JP2018523978A5 JP2017564379A JP2017564379A JP2018523978A5 JP 2018523978 A5 JP2018523978 A5 JP 2018523978A5 JP 2017564379 A JP2017564379 A JP 2017564379A JP 2017564379 A JP2017564379 A JP 2017564379A JP 2018523978 A5 JP2018523978 A5 JP 2018523978A5
- Authority
- JP
- Japan
- Prior art keywords
- bacterium
- induced
- deficiency
- gene
- genetically engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 239000004475 Arginine Substances 0.000 claims 7
- 108090000364 Ligases Proteins 0.000 claims 7
- 102000003960 Ligases Human genes 0.000 claims 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims 7
- 150000004666 short chain fatty acids Chemical class 0.000 claims 7
- 230000007613 environmental effect Effects 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 5
- 235000021391 short chain fatty acids Nutrition 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 206010020575 Hyperammonaemia Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010067125 Liver injury Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 231100000234 hepatic damage Toxicity 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 230000008818 liver damage Effects 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 239000006041 probiotic Substances 0.000 claims 2
- 230000000529 probiotic effect Effects 0.000 claims 2
- 235000018291 probiotics Nutrition 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 108010032178 Amino-acid N-acetyltransferase Proteins 0.000 claims 1
- 102000007610 Amino-acid N-acetyltransferase Human genes 0.000 claims 1
- 206010062695 Arginase deficiency Diseases 0.000 claims 1
- 208000034318 Argininemia Diseases 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 206010058297 Carbamoyl phosphate synthetase deficiency Diseases 0.000 claims 1
- 208000033910 Carbamoyl-phosphate synthetase 1 deficiency Diseases 0.000 claims 1
- 102000003846 Carbonic anhydrases Human genes 0.000 claims 1
- 108090000209 Carbonic anhydrases Proteins 0.000 claims 1
- 206010058892 Carnitine deficiency Diseases 0.000 claims 1
- 241001112696 Clostridia Species 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000007698 Gyrate Atrophy Diseases 0.000 claims 1
- 208000034596 Gyrate atrophy of choroid and retina Diseases 0.000 claims 1
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 claims 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 206010059521 Methylmalonic aciduria Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 108700043217 N-acetyl glutamate synthetase deficiency Proteins 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 claims 1
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 claims 1
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 claims 1
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 101150089004 argR gene Proteins 0.000 claims 1
- 201000003554 argininosuccinic aciduria Diseases 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 208000022843 carbamoyl phosphate synthetase I deficiency disease Diseases 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 238000002574 cystoscopy Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 201000011286 hyperargininemia Diseases 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000003694 methylmalonic acidemia Diseases 0.000 claims 1
- 208000012268 mitochondrial disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 claims 1
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 235000016236 parenteral nutrition Nutrition 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 201000004012 propionic acidemia Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000007845 reactive nitrogen species Substances 0.000 claims 1
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 1
- 229960003040 rifaximin Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 208000030954 urea cycle disease Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173710P | 2015-06-10 | 2015-06-10 | |
| US201562173706P | 2015-06-10 | 2015-06-10 | |
| US62/173,710 | 2015-06-10 | ||
| US62/173,706 | 2015-06-10 | ||
| US201562183935P | 2015-06-24 | 2015-06-24 | |
| US62/183,935 | 2015-06-24 | ||
| US201562184770P | 2015-06-25 | 2015-06-25 | |
| US201562184811P | 2015-06-25 | 2015-06-25 | |
| US62/184,811 | 2015-06-25 | ||
| US62/184,770 | 2015-06-25 | ||
| US201562248805P | 2015-10-30 | 2015-10-30 | |
| US62/248,805 | 2015-10-30 | ||
| US201562256039P | 2015-11-16 | 2015-11-16 | |
| US201562256041P | 2015-11-16 | 2015-11-16 | |
| US201562256048P | 2015-11-16 | 2015-11-16 | |
| US62/256,041 | 2015-11-16 | ||
| US62/256,039 | 2015-11-16 | ||
| US62/256,048 | 2015-11-16 | ||
| US201562263329P | 2015-12-04 | 2015-12-04 | |
| US62/263,329 | 2015-12-04 | ||
| US14/960,333 | 2015-12-04 | ||
| US14/960,333 US9487764B2 (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
| US201662277654P | 2016-01-12 | 2016-01-12 | |
| US62/277,654 | 2016-01-12 | ||
| US201662291468P | 2016-02-04 | 2016-02-04 | |
| US62/291,468 | 2016-02-04 | ||
| US201662293749P | 2016-02-10 | 2016-02-10 | |
| US62/293,749 | 2016-02-10 | ||
| PCT/US2016/020530 WO2016141108A1 (en) | 2015-03-02 | 2016-03-02 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| USPCT/US2016/020530 | 2016-03-02 | ||
| PCT/US2016/034200 WO2016200614A2 (en) | 2015-06-10 | 2016-05-25 | Bacteria engineered to treat diseases associated with hyperammonemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020217391A Division JP2021061846A (ja) | 2015-06-10 | 2020-12-25 | 高アンモニア血症に関連する疾患を治療するために操作された細菌 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523978A JP2018523978A (ja) | 2018-08-30 |
| JP2018523978A5 true JP2018523978A5 (enExample) | 2019-06-20 |
| JP6817966B2 JP6817966B2 (ja) | 2021-01-20 |
Family
ID=57504262
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564379A Expired - Fee Related JP6817966B2 (ja) | 2015-06-10 | 2016-05-25 | 高アンモニア血症に関連する疾患を治療するために操作された細菌 |
| JP2020217391A Pending JP2021061846A (ja) | 2015-06-10 | 2020-12-25 | 高アンモニア血症に関連する疾患を治療するために操作された細菌 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020217391A Pending JP2021061846A (ja) | 2015-06-10 | 2020-12-25 | 高アンモニア血症に関連する疾患を治療するために操作された細菌 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3307879A2 (enExample) |
| JP (2) | JP6817966B2 (enExample) |
| AU (1) | AU2016274311A1 (enExample) |
| CA (1) | CA2988930A1 (enExample) |
| WO (1) | WO2016200614A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136795A1 (en) | 2016-02-04 | 2017-08-10 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with tryptophan metabolism |
| BR112019024750A2 (pt) * | 2017-05-24 | 2020-06-09 | Thoeris Gmbh | uso de glutamina sintetase no tratamento da hiperamonemia |
| EP3720458A4 (en) * | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
| CN110446259B (zh) * | 2018-05-04 | 2022-04-15 | 大唐移动通信设备有限公司 | 一种寻呼机会的位置确定方法及通信设备 |
| KR20220003030A (ko) | 2019-04-29 | 2022-01-07 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수 |
| WO2020239882A1 (en) | 2019-05-30 | 2020-12-03 | Recordati Industria Chimica E Farmaceutica S.P.A. | Pharmaceutical formulation for carglumic acid |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| WO2021107500A1 (ko) | 2019-11-29 | 2021-06-03 | 주식회사 지니스 | 혈중 암모니아 수치 저하능을 갖는 균주 및 이를 포함하는 신경세포 보호용 조성물 |
| EP3839051A1 (en) * | 2019-12-19 | 2021-06-23 | Evonik Operations GmbH | Method for the fermentative production of guanidinoacetic acid |
| AU2021393455A1 (en) | 2020-12-02 | 2023-06-29 | Synlogic Operating Company, Inc. | Engineered microorganisms |
| EP4316685A4 (en) | 2021-03-31 | 2024-12-11 | Nippon Steel Corporation | NON-ORIENTED ELECTRICAL STEEL SHEET, METHOD FOR PUNCHING NON-ORIENTED ELECTRICAL STEEL SHEET, AND DIE FOR PUNCHING NON-ORIENTED ELECTRICAL STEEL SHEET |
| CN119592452B (zh) * | 2024-11-23 | 2025-12-02 | 清华大学 | 洋葱伯克霍尔德菌及其浸出废料中稀土元素的方法 |
| CN120000813A (zh) * | 2025-02-17 | 2025-05-16 | 温州医科大学 | 工程益生菌在防治阿尔茨海默病中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3083315B2 (ja) * | 1990-10-29 | 2000-09-04 | 株式会社ヤクルト本社 | 血中アンモニア低下剤 |
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| IT1290679B1 (it) * | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GEN NETWORKS FOR CONTROLLING GENE EXPRESSION |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| WO2009123029A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社 大塚製薬工場 | 血中アンモニア調整剤 |
| WO2015051323A1 (en) * | 2013-10-03 | 2015-04-09 | Trustees Of The University Of Pennsylvania | Compositions comprising a defined microbiome and methods of use thereof |
-
2016
- 2016-05-25 EP EP16731402.0A patent/EP3307879A2/en not_active Withdrawn
- 2016-05-25 CA CA2988930A patent/CA2988930A1/en not_active Abandoned
- 2016-05-25 WO PCT/US2016/034200 patent/WO2016200614A2/en not_active Ceased
- 2016-05-25 JP JP2017564379A patent/JP6817966B2/ja not_active Expired - Fee Related
- 2016-05-25 AU AU2016274311A patent/AU2016274311A1/en not_active Abandoned
-
2020
- 2020-12-25 JP JP2020217391A patent/JP2021061846A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523978A5 (enExample) | ||
| US9487764B2 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| JP7407120B2 (ja) | シンバイオティクス組成物 | |
| US20210095297A1 (en) | Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier | |
| JP6817966B2 (ja) | 高アンモニア血症に関連する疾患を治療するために操作された細菌 | |
| EP3307870B1 (en) | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid | |
| JP2018515106A5 (enExample) | ||
| CA2978315A1 (en) | Bacteria engineered to produce butyrate under low oxygen or anaerobic conditions and uses thereof | |
| Schöpping et al. | Stress response in bifidobacteria | |
| Qiao et al. | Metabolic profiles of cysteine, methionine, glutamate, glutamine, arginine, aspartate, asparagine, alanine and glutathione in Streptococcus thermophilus during pH-controlled batch fermentations | |
| JP2020525012A5 (enExample) | ||
| CN111655841A (zh) | 用于治疗紊乱的细菌 | |
| Wei et al. | Adaptational changes in physiological and transcriptional responses of Bifidobacterium longum involved in acid stress resistance after successive batch cultures | |
| EP3227440B1 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| Saraoui et al. | A unique in vivo experimental approach reveals metabolic adaptation of the probiotic Propionibacterium freudenreichii to the colon environment | |
| Xu et al. | Metabolic engineering of Lactococcus lactis for high level accumulation of glutathione and S-adenosyl-L-methionine | |
| van Bokhorst‐van de Veen et al. | Genotypic adaptations associated with prolonged persistence of Lactobacillus plantarum in the murine digestive tract | |
| WO2016210378A2 (en) | Multi-layered control of gene expression in genetically engineered bacteria | |
| EP3541942B1 (en) | Conjugative vectors selectable by fructooligosaccharides | |
| Sulek et al. | Metabolic footprint of Lactobacillus acidophilus NCFM at different pH | |
| Feng et al. | Either fadD1 or fadD2, which encode acyl-CoA synthetase, is essential for the survival of Haemophilus parasuis SC096 | |
| Jeong et al. | Lactobacillus Plantarum LRCC5314 Includes a Gene for a Substance that Stimulates the Secretion of Serotonin | |
| RU2799354C2 (ru) | Синбиотические композиции | |
| KAUR et al. | Mechanism of Endogenous Oxalate Synthesis and Its Degradation by Probiotic Bacteria in Humans. | |
| HK40038440A (en) | Synbiotic compositions |